Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
Human rIL-2, expressed and purified from Escherichia coli, is currently being tested as an anticancer therapeutic agent. Some of the patients undergoing clinical trials with rIL-2 have developed antibodies to rIL-2. We describe a chemical modification of rIL-2 that reduces its immunogenicity. rIL-2 has been chemically modified with a water soluble polymer, monomethoxy polyethylene glycol (PEG). This covalent conjugate PEG-rIL-2 has enhanced solubility and extended in vivo circulation. Attachment of PEG to rIL-2 reduces its immunogenicity when tested in rabbits and in mice. Ag-specific IgG antibody titers were 100 to 1000-fold lower when PEG-rIL-2 was used as the Ag, compared to rIL-2. In a long term study, 7 of 10 rabbits injected with PEG-rIL-2 had no Ag-specific IgG antibody response. In these seven rabbits, the in vivo behavior of the injected PEG-rIL-2 remained essentially unchanged after repeated immunizations. PEG-rIL-2 injected before rIL-2 injections, immunosuppressed the antibody response to rIL-2 in rabbits. The maintenance of the systemic exposure of PEG-rIL-2 after repetitive dosing is related to its decreased immunogenicity. Thus, the PEGylation (covalent attachment of PEG) of rIL-2-enhances its potential as an anticancer therapeutic.
Katre
N V
NV
Cetus Corporation, Emeryville, CA 94608.
D000818:Animals; D001682:Biological Availability; D004306:Dose-Response Relationship, Immunologic; D007165:Immunosuppression Therapy; D007376:Interleukin-2 / Q000031:analogs & derivatives* / Q000276:immunology / Q000493:pharmacokinetics; D011092:Polyethylene Glycols; D011817:Rabbits; D011994:Recombinant Proteins / Q000276:immunology / Q000493:pharmacokinetics
D007376:Interleukin-2; D011994:Recombinant Proteins; D011092:Polyethylene Glycols